

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



绿竹生物
LUZHU BIOTECH

Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

INSIDE INFORMATION

THE H SHARE FULL CIRCULATION

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

INTRODUCTION

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated December 28, 2023 and January 17, 2024 in relation to the proposed participation in the H share full circulation programme by the Company and the issuance of filing notice by CSRC of the Application (the “**Announcements**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The Company has applied to the Listing Committee of the Stock Exchange for the approval of the listing of and permission to deal in 59,729,296 H Shares (the “**Converted H Shares**”), representing the maximum number of the Unlisted Shares. The Company is pleased to announce that the listing approval was granted by the Stock Exchange on January 29, 2024 (the “**Listing Approval**”).

SHAREHOLDING STRUCTURE OF THE COMPANY BEFORE AND AFTER THE COMPLETION OF THE CONVERSION AND LISTING

The Conversion and Listing will involve a total of two participating shareholders (the “**Participating Shareholders**”) of 59,729,296 Unlisted Shares, who will, after the Conversion and Listing, hold approximately 29.50% of the total issued H Shares. Set out below is the percentage holding of the Participating Shareholders upon completion of the Conversion and Listing.

Name of the Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued H Shares upon completion of the Conversion and Listing
Mr. KONG Jian (孔健)	58,294,513	28.79%
Beijing Xinyin Xinghong Equity Investment Partnership (Limited Partnership) (北京信銀興弘股權投資合夥企業(有限合夥))	1,434,783	0.71%
Total	<u>59,729,296</u>	<u>29.50%</u>

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Class of Shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	Number of Shares	Approximate percentage	Number of Shares	Approximate percentage
Unlisted Shares	59,729,296	29.50%	–	–
H Shares	142,719,736	70.50%	202,449,032	100.00%
Total	<u>202,449,032</u>	<u>100.00%</u>	<u>202,449,032</u>	<u>100.00%</u>

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in compliance with the requirements under the Listing Rules and the applicable laws, as and when appropriate.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, January 29, 2024

As at the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshe and Ms. HOU Aijun as independent non-executive Directors.